Phase 1 N=41 Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women
HIV Infection
Primary: Infant Gestational Age at Delivery — 38; 38 Weeks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=5 Antidepressant Effects of NR2B in Major Depression
Major Depression
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — 22.519; 23.633 Score on a scale — p=.272
Phase 1 N=34 Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))
Multiple Myeloma
Primary: Mean Duration of Treatment With Vorinostat — 4.6; 72.6; 107.1 Days
Phase 1 N=40 SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fed Admin
Prostatic Hyperplasia
Primary: AUC 0-t — 229.87; 220.85 ng per hour per ml (ng.h/ml)
Phase 1 N=20 Bioequivalence Study Comparing Linezolid 600 Mg Oral Suspension With 600 Mg Tablet In Chinese Healthy Male Subjects
Healthy Volunteers
Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) — 108.90; 112.00 microgram*hour/milliliter (mcg*h/mL)
Phase 1 N=48 A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate
Erectile Dysfunction
Primary: Area Under the Curve (AUC 0-t) — 1467.00; 1458.45; 1493.53 ng*hr/mL
Phase 1 N=40 SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fast Admin
Prostatic Hyperplasia
Primary: AUC0-t — 237.35; 226.74 ng per hour per ml (ng/h/ml)
Phase 1 N=22 Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.
Acquired Immunodeficiency Syndrome
Primary: Plasma Lopinavir/Ritonavir Concentrations as Measured by the Area Under the Curve (AUC 0-12h). — 99599; 73603; 45146 ng.h/mL — p=<0.05
Phase 1 N=24 Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)
Type 2 Diabetes Mellitus
Primary: Saxagliptin Mean Maximum Observed Plasma Concentration (Cmax) — 8.57; 8.61; 11.36; 11.51 ng/mL
Phase 1 N=18 Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fed Conditions
Healthy
Primary: Cmax of Venlafaxine. — 81.84; 93.50 ng/mL
Phase 1 N=24 Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Sprinkle Study
Healthy
Primary: Cmax of Venlafaxine. — 120.07; 103.59 ng/mL
Phase 1 N=19 Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers
Healthy
Primary: Average Pain (0-120 Seconds): Cold Pain Test Visual Analog Scale (VAS) — 45.2; 45.5; 45.0; 44.9 mm
Phase 1 N=50 Study in Healthy Volunteers to Prove That Two Different Formulations of Rotigotine Patches Deliver Equivalent Drug Amount to the Body
Healthy Volunteers
Primary: AUC(0-tz) of Unconjugated Rotigotine — 5.2704; 5.4724 ng/ mL*h
Phase 1 N=18 Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Attention-Deficit Hyperactivity Disorder
Primary: Power of Attention Score — 1260.7; 1324.1; 1272.8; 1244.6 milliseconds
Phase 1 N=106 A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED)
Alzheimer's Disease
Primary: Change in Mean Computer-based Cognitive Assessment (CogState) Composite Score at Week 4 — -0.10; -0.07 Score on a scale — p=0.231